Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Enzo Biochem, Inc. (NYSE: ENZ).

Full DD Report for ENZ

You must become a subscriber to view this report.


Recent News from (NYSE: ENZ)

Enzo Biochem, Inc. (ENZ) Q1 2019 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Q1 2019 Earnings Conference Call December 11, 2018 08:30 ET Executives Barry Weiner - President, Chief Financial Officer and Principal Accounting Officer Jim O'Brien - Executive Vice President, Finance Analysts Per Ostlund - Craig-Hallum Capital Jef...
Source: SeekingAlpha
Date: December, 11 2018 14:48
Enzo Biochem misses by $0.02, beats on revenue
Enzo Biochem (NYSE: ENZ ): Q1 GAAP EPS of -$0.13 misses by $0.02 . More news on: Enzo Biochem, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: December, 10 2018 16:18
Enzo Biochem Reports Fiscal 2019 First Quarter Results
Recent Reimbursement Cuts Emphasize Value of Enzo’s Strategy Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported operating results for the first fiscal quarter ended October 31, 2018, in addition to providing an update on the compan...
Source: Business Wire
Date: December, 10 2018 16:15
Enzo Biochem Schedules Teleconference to Discuss First Quarter 2019 Results Tuesday, December 11, 2018 at 8:30 AM E.T.
Enzo Biochem, Inc . (NYSE:ENZ), an integrated diagnostic and therapeutics company, will hold a conference call to discuss fiscal 2019 first quarter results Tuesday, December 11, 2018, at 8:30 AM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-...
Source: Business Wire
Date: December, 06 2018 09:00
Enzo Biochem Reports Publication of Study on Therapeutic Candidate SK1-I Detailing Promising Results in a Model of Treatment-Resistant Breast Cancer
Drug Candidate SK1-I Shown to Reverse Tamoxifen Resistance in Human Breast Cancer Preclinical Study Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and therapeutics company, today reported the publication of a study in the Journal of Lipid Research by researchers at a collabo...
Source: Business Wire
Date: December, 03 2018 09:00
Enzo Biochem- Genetics and Diagnostics
Enzo Biochem ( ENZ ) researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology, explains Bill Mathews , small cap specialist and editor of The Cheap Investor . Its products are used by scientifi...
Source: MoneyShow.com
Date: November, 01 2018 01:00
Market Trends Toward New Normal in Polaris Industries, NIKE, Charles River Laboratories International, Actuant, Caesarstone, and Enzo Biochem - Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Oct. 29, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Polaris Industries Inc. (NYSE:PII), NIKE, Inc. (NYSE:NKE), Charles Riv...
Source: GlobeNewswire
Date: October, 29 2018 08:25
Enzo Biochem Trades At A Discount To Its Sum Of The Parts Value With Multiple Ways To Win
Enzo Biochem Inc. ( ENZ ) was founded by Dr. Elazar Rabbani in 1976. Dr. Rabbani, a pioneer in labeling and detection of the molecular diagnostics products, is the company’s CEO and Chairman. He is joined by co-founder and President, Barry Weiner. ENZ came to our attention one year ag...
Source: SeekingAlpha
Date: October, 22 2018 09:00
Enzo Biochem, Inc. (ENZ) Q4 2018 Results - Earnings Call Transcript
Enzo Biochem, Inc. (ENZ) Q4 2018 Results Earnings Conference Call October 16, 2018, 08:30 AM ET Executives Barry Weiner - President, CFO, Principal Accounting Officer and Director Jim O'Brien - EVP, Finance Analysts Per Ostlund - Craig Hallum Presentation Operator G...
Source: SeekingAlpha
Date: October, 16 2018 13:15
Enzo Biochem misses by $0.06, misses on revenue
Enzo Biochem (NYSE: ENZ ): Q4 Non-GAAP EPS of -$0.12 misses by $0.06 . More news on: Enzo Biochem, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: October, 15 2018 16:12

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-144.734.784.814.6584,170
2017-11-279.359.539.649.3591,110
2017-11-249.499.429.579.2741,176
2017-11-229.519.489.739.4783,849
2017-11-219.349.499.529.34132,855

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1893159,0631.5763Cover
2018-12-171,06246,3762.2900Cover
2018-12-149619,1650.5009Cover
2018-12-1332726,7261.2235Cover
2018-12-121,4537,53019.2961Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ENZ.


About Enzo Biochem, Inc. (NYSE: ENZ)

Logo for Enzo Biochem, Inc. (NYSE: ENZ)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $304,566,020 - 05/18/2018
  • Issue and Outstanding: 47,000,929 - 03/01/2018

 


Recent Filings from (NYSE: ENZ)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: August, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 18 2018
An annual report of employee stock purchase savings and similar plans
Filing Type: 11-KFiling Source: edgar
Filing Date: June, 29 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: June, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: March, 12 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 02 2018

 

 


Daily Technical Chart for (NYSE: ENZ)

Daily Technical Chart for (NYSE: ENZ)


Stay tuned for daily updates and more on (NYSE: ENZ)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: ENZ)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ENZ is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ENZ and does not buy, sell, or trade any shares of ENZ. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/